[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EG17134A - Method and composition for the preparation of controlled long acting pharmaceuticals for oral administration - Google Patents

Method and composition for the preparation of controlled long acting pharmaceuticals for oral administration

Info

Publication number
EG17134A
EG17134A EG733/84A EG73384A EG17134A EG 17134 A EG17134 A EG 17134A EG 733/84 A EG733/84 A EG 733/84A EG 73384 A EG73384 A EG 73384A EG 17134 A EG17134 A EG 17134A
Authority
EG
Egypt
Prior art keywords
preparation
composition
oral administration
long acting
controlled long
Prior art date
Application number
EG733/84A
Other languages
English (en)
Original Assignee
Lowey Hans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lowey Hans filed Critical Lowey Hans
Application granted granted Critical
Publication of EG17134A publication Critical patent/EG17134A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EG733/84A 1983-12-01 1984-12-01 Method and composition for the preparation of controlled long acting pharmaceuticals for oral administration EG17134A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/556,844 US4680323A (en) 1983-12-01 1983-12-01 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration

Publications (1)

Publication Number Publication Date
EG17134A true EG17134A (en) 1991-08-30

Family

ID=24223083

Family Applications (1)

Application Number Title Priority Date Filing Date
EG733/84A EG17134A (en) 1983-12-01 1984-12-01 Method and composition for the preparation of controlled long acting pharmaceuticals for oral administration

Country Status (26)

Country Link
US (1) US4680323A (fr)
JP (1) JPS60185728A (fr)
KR (1) KR930000046B1 (fr)
AT (1) AT394948B (fr)
AU (1) AU572571B2 (fr)
BE (1) BE901186A (fr)
CA (1) CA1229551A (fr)
CH (1) CH664970A5 (fr)
DE (1) DE3443587C2 (fr)
DK (1) DK162511C (fr)
EG (1) EG17134A (fr)
FI (1) FI82601C (fr)
FR (1) FR2555901B1 (fr)
GB (1) GB2152940B (fr)
HU (1) HU193717B (fr)
IE (1) IE58112B1 (fr)
IL (1) IL73594A (fr)
IT (1) IT1177152B (fr)
LU (1) LU85660A1 (fr)
MX (1) MX161165A (fr)
NL (1) NL193164C (fr)
NO (1) NO167002C (fr)
NZ (1) NZ210310A (fr)
PT (1) PT79427B (fr)
SE (1) SE461071B (fr)
ZA (1) ZA849373B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153105B1 (fr) * 1984-02-10 1992-09-09 Benzon Pharma A/S Dose à base d'unités multiples enrobées par une couche de diffusion
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
EP0205336B1 (fr) * 1985-06-11 1991-09-11 Teijin Limited Préparation pharmaceutique orale à effet entretenn
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
IL85538A (en) * 1987-02-27 1991-09-16 Lilly Co Eli Sustained release matrix tablet formulations containing hydrophilic and enteric polymers
US4783331A (en) * 1987-06-29 1988-11-08 Miles Inc. Method for solubilization of aspartame in effervescent aqueous systems; and composition
AU2252388A (en) * 1988-05-02 1989-11-29 Zila Pharmaceuticals Compositions and in situ methods for forming films on body tissue
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
DK0542926T3 (da) * 1990-08-07 1995-05-15 Pfizer Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
EP0580861B1 (fr) * 1991-04-08 1998-09-09 Nippon Shinyaku Company, Limited Capsule à liberation soutenue pour adhèsion dans le tractus gastrointestinal
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
NO924985L (no) * 1991-12-30 1993-07-01 Akzo Nv Thyroaktiv blanding med vedvarende frigjoering
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
RU2192245C2 (ru) * 1996-05-13 2002-11-10 Новартис Консьюмер Хелс С.А. Трансбуккальная система доставки
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US6479082B1 (en) 1996-12-23 2002-11-12 Wm. Wrigley, Jr. Co. Process of increasing flavor release from chewing gum using hydroxypropyl cellulose and product thereof
CA2216215A1 (fr) 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
NZ504418A (en) * 1997-11-12 2003-02-28 Boehringer Mannheim Pharm Corp Delayed release oral dosage form of carvedilol
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
AU1649700A (en) * 1998-12-22 2000-07-12 Novo Nordisk A/S Novel formulation
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE60037799D1 (de) 1999-04-01 2008-03-06 Wrigley W M Jun Co Strukturen mit langanhaltender geschmacksabgabe fuer kaugummi
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
WO2002045695A2 (fr) 2000-12-05 2002-06-13 Alexander Macgregor Systeme de distribution hydrostatique regulee d'un agent
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
WO2004037228A1 (fr) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Compositions a liberation prolongee contenant de l'alfuzosine
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
CA2518650A1 (fr) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Formule a base de toxine de clostridium botulinum et methode permettant de perdre du poids
MX2007005277A (es) 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Formulaciones de bacteriofagos estabilizadas.
CA2620259A1 (fr) * 2005-08-23 2007-03-01 Nissan Chemical Industries, Ltd. Preparation a liberation retardee
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
JP2010518021A (ja) * 2007-01-31 2010-05-27 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Ｓ−アデノシルメチオニンの持続放出医薬製剤
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008102235A1 (fr) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Formulations d'alfuzosine à libération contrôlée
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
KR100836960B1 (ko) * 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US8445020B2 (en) * 2008-05-19 2013-05-21 Pharmalyte Solutions, Llc High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
EP3288570A4 (fr) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Cellules souches modifiées et leurs utilisations
WO2017062997A1 (fr) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Formulation pharmaceutique
CN115429815B (zh) * 2021-06-02 2023-12-22 广州帝奇医药技术有限公司 一种长效饱腹组合物、制备方法及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
US3590117A (en) * 1969-03-24 1971-06-29 Richardson Merrell Inc Long-lasting troche containing guar gum
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
CA945899A (en) * 1971-09-16 1974-04-23 Hans Lowey Long-acting oral carrier
GB1430684A (en) * 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
US3876771A (en) * 1973-09-04 1975-04-08 Hallister Inc Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS55118414A (en) * 1979-03-05 1980-09-11 Teijin Ltd Prolonged release drug and its preparation
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
CA1146866A (fr) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS58192817A (ja) * 1982-05-06 1983-11-10 Nippon Soda Co Ltd 棒状製剤の製造方法
CA1208558A (fr) * 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
IT1177152B (it) 1987-08-26
KR850004392A (ko) 1985-07-15
FR2555901A1 (fr) 1985-06-07
IT8423523A0 (it) 1984-11-09
SE8406081D0 (sv) 1984-11-30
FI82601B (fi) 1990-12-31
ZA849373B (en) 1985-07-31
CH664970A5 (de) 1988-04-15
NZ210310A (en) 1988-01-08
GB8430083D0 (en) 1985-01-09
HU193717B (en) 1987-11-30
IE58112B1 (en) 1993-07-14
IT8423523A1 (it) 1986-05-09
FI82601C (fi) 1991-04-10
NO844280L (no) 1985-06-03
JPS60185728A (ja) 1985-09-21
DK162511C (da) 1992-03-30
NL193164B (nl) 1998-09-01
FI844656L (fi) 1985-06-02
US4680323A (en) 1987-07-14
PT79427B (en) 1986-09-15
IL73594A (en) 1988-12-30
ATA382484A (de) 1992-01-15
PT79427A (en) 1984-11-01
DE3443587A1 (de) 1985-06-27
NL193164C (nl) 1999-01-05
SE8406081L (sv) 1985-06-02
SE461071B (sv) 1990-01-08
GB2152940B (en) 1987-09-03
FI844656A0 (fi) 1984-11-27
DK569784D0 (da) 1984-11-30
GB2152940A (en) 1985-08-14
MX161165A (es) 1990-08-09
AT394948B (de) 1992-07-27
DK162511B (da) 1991-11-11
FR2555901B1 (fr) 1988-06-10
IL73594A0 (en) 1985-02-28
KR930000046B1 (ko) 1993-01-06
HUT35531A (en) 1985-07-29
AU572571B2 (en) 1988-05-12
AU3449984A (en) 1985-06-06
NO167002C (no) 1991-09-25
NO167002B (no) 1991-06-17
IE843077L (en) 1985-06-01
CA1229551A (fr) 1987-11-24
NL8403522A (nl) 1985-07-01
DE3443587C2 (de) 1986-11-06
LU85660A1 (de) 1985-06-04
BE901186A (fr) 1985-03-15
DK569784A (da) 1985-06-02

Similar Documents

Publication Publication Date Title
EG17134A (en) Method and composition for the preparation of controlled long acting pharmaceuticals for oral administration
PT81746A (en) Process for the preparation of peptide-aldehydes and of pharmaceutical compositions containing them
NZ208959A (en) Insulin derivatives and pharmaceutical compositions
PT81007A (en) Process for the preparation of analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives and of pharmaceutical compositions containing the same
PT81015B (en) Process for the preparation of piridazo-diazocine derivatives and pharmaceutical compositions therewith
DE3267673D1 (en) Phospholipid derivatives, processes for preparation thereof and pharmaceutical composition of the same
DE3366393D1 (en) Phospholipid derivatives, process for preparation thereof and pharmaceutical composition of the same
PH18979A (en) Banzazepine derivatives,their pharmaceutical compositions and method of use
ZA821196B (en) Substituted benzimidazolones and salts thereof, methods of preparation and pharmaceutical compositions thereof
PT78813A (en) Process for the preparation of pharmaceutical composition containing xanthan gum and locust bean gum
EG17710A (en) Process for the preparation isosilybin-free silbinin and pharmaceutical compositions containing them
PT82984A (en) Process for the preparation of poly-4-aminopyrrole-2-carboxamido derivatives and of pharmaceutical compositions containing the same
PT79858B (en) Process for the preparation of azolyl-aryl-alcanol and pharmaceutical compositions therewith
PT80824B (en) Process for the preparation of phenylquinoline derivatives and of pharmaceutical compositions containing the same
PT82772A (en) Process for the preparation of novel glycerol derivatives and of pharmaceutical compositions containing the same
NZ208694A (en) Rooperol derivatives and pharmaceutical compositions
PT79199A (en) Process for preparing 3-indolecarboxamide derivatives and of pharmaceutical compositions containing the same
PT75265A (en) Process for the preparation of diazabicyclicononanes substituted and pharmaceutical composition containing them
PT81083A (en) Process for the preparation of substituted 7-oxomitosanes and of pharmaceutical compositions containing the same
IL71470A0 (en) Novel galenic forms of sulpirid suitable for oral administration and their preparation
PT83231A (en) Process for the preparation of gem-dihalo-1,8-diamino-4-aza-octanes and of pharmaceutical compositions containing the same
NZ207806A (en) Benzothienyl-cephalosporin derivatives and pharmaceutical compositions
DE3267034D1 (en) Phospholipid derivatives, process for preparation thereof and pharmaceutical composition of the same
PT79990B (en) Process for the preparation of diazepine-indoles and of pharmaceutical compositions therewith
PH22356A (en) Method and composition for the preparation of controlled long acting pharmaceuticals for oral administration